Alcon extends Lifecore pact to 2034 as Alcon stock gains 1.25 percent

Published on 10/07/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 3.95 percent to CHF 2.23 billion from CHF 2.15 billion. Alcon stock costs EUR 56.79 on October 7, 2026 after EUR 56.09.

Financial editorial photography of glowing trading monitors. Screens display EYE CARE, OPHTHALMOLOGY sector data, SIX SWISS EXCHANGE text with upward trending candlestick charts, green on dark blue, shallow depth of field — Alcon CH0432492467: Handelsterminals zeigen EYE CARE, OPHTHALMOLOGY und SIX SWISS EXCHANGE mit steigenden Charts, Illustration mit AI erstellt.

Alcon stock (ISIN CH0432492467) was trading at EUR 56.79 at Lang & Schwarz on October 7, 2026 at 10:38 a.m. CEST, up 1.25 percent from the EUR 56.09 prior close. Stock-World reported that Alcon is extending its manufacturing agreement with Lifecore Biomedical through December 31, 2034.

Lifecore agreement reaches 2034

The amended contract extends the previous December 31, 2031 expiration by three years, with the new arrangement taking effect on November 1, 2026, according to Stock-World. The agreement gives Alcon a longer planning horizon for manufacturing capacity in its contact lens business. The source also reported the introduction of the Precision7 weekly replacement contact lens by Alcon ANZ.

Q2 revenue adds operating support

Alcon's second-quarter 2026 revenue rose 3.95 percent year over year to CHF 2.23 billion from CHF 2.15 billion, according to finanzen.ch. The report listed a loss per share of CHF 0.00 for the quarter, compared with a loss of CHF 0.30 in the prior-year quarter. The revenue comparison gives the contract news a measurable operating backdrop, although the next quarterly report remains the larger test for demand and margins.

Stock remains below yearly high

MarketBeat lists Alcon's NYSE 52-week range at USD 61.84 to USD 87.64 and market capitalization at USD 30.8 billion as of October 6, 2026. Its average price target is USD 84.43, while the consensus rating is Moderate Buy, according to MarketBeat. The target and current US quote use dollars and therefore provide separate NYSE context rather than a replacement for the euro reference price.

EUR price gains 1.25 percent

At Lang & Schwarz, Alcon was trading at EUR 56.79 on October 7, 2026 at 10:38 a.m. CEST, plus 1.25 percent versus the EUR 56.09 prior close. On the NYSE, the stock was last at USD 63.19 on October 6, 2026 at 4:00 p.m. ET, within a USD 61.84 to USD 87.64 52-week range. The further course of trading is shown by the continuously updated real-time quote of Alcon stock.